Integra LifeSciences (NASDAQ:IART) Stock Price Down 4.7%

Integra LifeSciences Holdings Co. (NASDAQ:IART) shares traded down 4.7% during trading on Friday . The company traded as low as $30.11 and last traded at $30.13. 303,617 shares traded hands during mid-day trading, a decline of 53% from the average session volume of 640,214 shares. The stock had previously closed at $31.63.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target for the company in a report on Wednesday, April 3rd. Truist Financial cut their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. Finally, JMP Securities dropped their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research note on Thursday, February 29th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $44.89.

Integra LifeSciences Stock Performance

The stock’s 50-day moving average is $37.12 and its 200-day moving average is $39.14. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 37.89, a PEG ratio of 0.96 and a beta of 1.12.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. During the same quarter last year, the business posted $0.94 earnings per share. Integra LifeSciences’s revenue was down .3% compared to the same quarter last year. On average, analysts predict that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors have recently made changes to their positions in the company. Capital Research Global Investors lifted its stake in shares of Integra LifeSciences by 40.1% in the 4th quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock valued at $187,149,000 after purchasing an additional 1,228,996 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new position in Integra LifeSciences in the third quarter valued at $43,034,000. Select Equity Group L.P. purchased a new stake in Integra LifeSciences during the fourth quarter valued at about $47,199,000. Norges Bank purchased a new position in Integra LifeSciences in the fourth quarter valued at about $39,872,000. Finally, Assenagon Asset Management S.A. acquired a new stake in Integra LifeSciences during the third quarter valued at approximately $25,443,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.